Food and Drug Administration (FDA)

documents

Benchmarking Dissent Processes and Best Practices

letters

POGO Opposes Califf Nomination Due to Conflicts of Interest POGO Urges Senate to Vote Against Nominee to the FDA POGO Asks President to Withdraw FDA Nominee POGO Letter to Associate Commissioner Warner, FDA, Questioning FDA's Handling of Conflicts of Interest on FDA Advisory Committees POGO and Partners Oppose House Bill that Allows FDA More Secrecy POGO and Groups Support Better Information on Clinical Trials POGO and Partners Oppose FDA Secrecy POGO Letter: FDA Advisors on Yaz and Yasmin Have Industry Ties POGO Letter Urges FDA Not to Weaken Conflict of Interest Standards at Center for Drug Evaluation and Research POGO Letter to FDA Commissioner Hamburg Concerning the Potentially Dangerous Interaction of the Drugs Seroquel and Methodone POGO Asks DHHS Secretary Sebelius to Reinvestigate FDA's Negligent Oversight of Unsafe Medical Devices POGO Letter to FDA Commissioner Margaret Hamburg Regarding Potentially Dangerous Drug Interaction Invovling Seroquel and Methadone POGO's letter to Deputy HHS IG on FDA's CDRH's low standard of medical devices approval The Finances Of FDA Advisory Committee Members: If Information Must Be Withheld, Let It Be Done Openly POGO's letter to Commissioner Hamburg regarding medical devices POGO Letter to FDA's Daniel Schultz MD regarding a policy decision by CDRH to discontinue inspections of nonclinical laboratories POGO Asks FDA Head to Have Deadly Syringe Incident Investigated POGO letter to FDA's Daniel Schultz MD regarding the lack of GLP inspections POGO Follow-up letter to CDRH Director Daniel Schultz POGO Letter to CDRH Director Daniel Schultz regarding a series of questions about the apparent decision not to enforce the GLP regulation

Latest

Avoiding the Subject: On Pfizer Vaccine Quality Control, FDA Says Less than European Counterpart

investigation | March 19, 2021

Latest

Hearing Without Listening

analysis | December 16, 2020

2017 Baker’s Dozen of Suggested Congressional Oversight Priorities and Legislative Reforms

report | March 28, 2017
Trump’s Dangerous Prescription for the FDA

investigation | March 3, 2017
FDA Set Low Bar for Approval of Blood Thinners

analysis | December 12, 2016
UPDATE: DOJ Subpoenas Maker of Faulty Blood Testing Devices Spotlighted by POGO

analysis | August 12, 2016
Faulty Blood Testing Devices to Be Withdrawn from Market

analysis | July 13, 2016
FDA Says Faulty Devices Had "Minimal" Impact on Trial Led by New Boss

analysis | July 13, 2016
POGO Wins National Journalism Prize for Reporting on FDA

analysis | April 22, 2016
FDA to Tighten Standards for Blood-Test Devices

analysis | March 24, 2016